Media stories about MISONIX (NASDAQ:MSON) have trended positive this week, according to Accern Sentiment. Accern identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. MISONIX earned a news impact score of 0.26 on Accern’s scale. Accern also assigned press coverage about the medical equipment provider an impact score of 44.8965432708339 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Shares of NASDAQ MSON opened at $10.90 on Thursday. MISONIX has a 1-year low of $7.05 and a 1-year high of $11.80.
MISONIX (NASDAQ:MSON) last posted its quarterly earnings results on Tuesday, February 6th. The medical equipment provider reported ($0.11) earnings per share (EPS) for the quarter. MISONIX had a negative return on equity of 11.13% and a negative net margin of 28.12%. The company had revenue of $8.32 million for the quarter.
Separately, TheStreet cut MISONIX from a “c-” rating to a “d” rating in a report on Friday, February 9th.
In related news, Director Thomas M. Patton purchased 5,000 shares of MISONIX stock in a transaction that occurred on Wednesday, February 14th. The shares were acquired at an average cost of $10.20 per share, for a total transaction of $51,000.00. Following the transaction, the director now directly owns 500 shares in the company, valued at $5,100. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last 90 days, insiders have purchased 6,800 shares of company stock worth $69,540. 23.80% of the stock is owned by corporate insiders.
MISONIX Company Profile
Misonix, Inc, together with its subsidiaries, designs, develops, manufactures, and markets therapeutic ultrasonic medical devices in the United States and internationally. The company offers BoneScalpel, an ultrasonic bone cutting and sculpting system for surgical procedures involving the precise cutting of bone while sparing soft tissue; SonaStar, a surgical aspirator that is used to emulsify and remove soft and hard tumors; and SonicOne, an ultrasonic cleansing and debridement system, which provides tissue specific debridement and cleansing of wounds and burns for the removal of devitalized tissue and fibrin deposits while sparing viable cells, as well as other medical devices.
Receive News & Ratings for MISONIX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MISONIX and related companies with MarketBeat.com's FREE daily email newsletter.